SARomics Biostructures has entered into a strategic drug discovery partnership with inSili.com.
The two companies are to perform collaborative research with the goal of finding novel bioactive agents against therapeutic drug targets. The focus of the collaboration aims at identifying new lead- and drug-like molecular entities with innovative modes of action, and obtaining structures of macromolecular receptor-ligand complexes. The ambition is that the collaborative platform will enable the discovery of orthosteric as well as allosteric effector molecules to innovate small molecule drug discovery.
“We are excited about the opportunity to collaborate with inSili.com in a way that clearly leverages the strength and competitiveness of both companies. We see this initiative as ideally complementary to our other research collaborations.” Dr. Björn Walse, CEO of SARomics Biostructures.
Zürich-based inSili.com was founded in 2013 as an ETH spin-off company to provide innovative molecular design and drug discovery
services to the pharmaceutical, biotech and chemical industries. The company’s computational technology platform generates new molecular entities with multi-target activity profiles or designer selectivity.